Terminal beta-galactose residues on cell-surface glycoconjugates (Terminal beta-Gal)

Terminal beta-galactose residues are carbohydrate structures found at the distal ends of glycan chains on cell-surface glycoproteins and glycolipids. These residues are essential for biological recognition, acting as specific ligands for endogenous lectins like galectins and the asialoglycoprotein receptor (ASGPR) (Johannes et al., 2018, J. Cell Sci.). In normal physiology, they regulate the circulatory half-life of glycoproteins; as sialic acid is removed, exposed terminal galactose residues signal for hepatic clearance (D'Souza & Devarajan, 2015, J. Control Release). In pathological states, particularly cancer, the expression patterns of terminal galactose change significantly, often leading to the exposure of the Thomsen-Friedenreich (TF) antigen (Yu, 2007, Glycoconj. J.). This altered glycosylation is associated with increased tumor cell adhesion, metastasis, and immune evasion. Therapeutic strategies exploit these residues for targeted drug delivery, particularly to the liver, or involve the use of lectin-inhibitors to disrupt disease-promoting interactions. Additionally, certain potent toxins, such as ricin and abrin, utilize terminal galactose residues as docking sites to facilitate cellular entry and subsequent toxicity.

Other names

Terminal beta-D-galactoseGalactose-terminated glycansNon-sialylated galactose residuesbeta-galactosyl residuesCD176 (when part of TF antigen)

Binding to carbohydrate-recognition domains (CRDs) of lectins or toxins, facilitating cellular entry via endocytosis or mediating cell-cell adhesion and signaling.